scholarly journals The Effect of Urtica Dioica Extract on Blood Lipids Profile in Patients with Type 2 Diabetes: A Randomized Double-blinded Clinical Trial

2021 ◽  
Author(s):  
Roya Khajeh Mehrizi ◽  
Hassan Mozaffari-Khosravi ◽  
Parisa Aboee
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Clinical Trial ◽  
Total Cholesterol ◽  
Density Lipoprotein ◽  
Urtica Dioica ◽  
Significant Difference ◽  
The Mean ◽  
Double Blinded

Background: Diabetes is an endocrine disorder that is strongly associated with cardiovascular disease. The use of alternative therapy has recently increased and medicinal plants are one of the alternative therapies for diabetic patients. This study aimed to evaluate the protective effect of Urtica dioica (Nettle) on lipid profile in patients with type 2 diabetes (T2D). Method: This parallel randomized double-blinded clinical trial was conducted on 60 men and women with T2D for an 8-week period. The participants were randomly assigned to received 100mg/kg/day extract of Urtica Dioica (UG) and the placebo group (PG). Blood triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDLc) and high density lipoprotein cholesterol (HDLc) were measured at baseline and end of the study. The data were analyzed using SPSS 16.0 and P < 0.05 was considered significant. Results: The mean difference of total cholesterol showed no significant difference in the UG compared to the PG which were -10.56±40.5 and -19.5± 35.9 (P = 0.14), respectively. The study also showed no significant difference between TG and LDLc in the UG compared to the PG (-39.8±171.5 vs. -23.37±72.3 (P = 0.68) and -3.16±33.4 vs. -11.2±35.6 (P = 0.15), respectively). The mean difference of HDLc in the UG and PG were -2.68±8.11 and 2.62±10.6 (P = 0.05), respectively, indicating a significant increase in the UG compared to the PG. Conclusion: The results demonstrated that consumption of 100mg/kg/day extract of UD for 8 weeks by increasing HDL concentration can decrease the risk of cardiovascular disease in patients with T2D.

scholarly journals Gender based variation of lipid abnormalities in type-2 diabetes mellitus patients

2021 ◽  
Vol 9 (10) ◽  
pp. 3068
Author(s):  
Arpita Jaidev ◽  
Hitesh Shah ◽  
Liggy Andrews ◽  
Bhavisha N. Vagheda
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Total Cholesterol ◽  
Blood Sugar ◽  
Density Lipoprotein ◽  
Diabetic Patients ◽  
Male And Female ◽  
Significant Difference

Background: Dyslipidemia has a varying pattern among the male and female patients of type 2 diabetes mellitus (DM).Methods: This study was conducted in the out-patient department (OPD) of department of medicine at GMERS, Patan, Gujarat from July 2020 to December 2020 for a period of six months. Fasting blood sugar, hemoglobin A1c (FBS, HbA1c) lipid profile triacylglycerol-triglyceride, total cholesterol, low density lipoprotein cholesterol and high-density lipoprotein cholesterol (TG, TC, LDL-C, and HDLC) were measured. Statistical analyses were performed with the SPSS software program.Results: A total number of 200 type 2 DM patients (100 males and 100 females) attending to GMERS OPD were recruited in this study. Blood sugar was higher than normal in both male and female (FBS=142.44±36.21, 146.40±41.49 respectively). TG level was also higher in two groups of study subjects with female level slightly more than male (164.99±67.1and 138.21±70 respectively) with no significant difference between the groups (p>0.05).Total cholesterol and LDL-C level was within normal physiological level in both groups, where-as these levels were higher in female in comparison to male (TC=198.07±40.82 and 169.5±36.13 respectively, LDLC=118±34 and 99±27, respectively), showing significant difference between the groups (p=0.014). HDL-C was not below normal in both male (41±5.4) and female (43.99±4.31); however, HDL-C was slightly higher in female than male and the difference was significant (p=0.0129).Conclusions: Dyslipidemia was noticed in a greater proportion of female diabetic patients than male diabetic patients.

scholarly journals The Effect of Bread Enriched With Portulaca Oleracea on Metabolic Control Indices in Patients With Type 2 Diabetes: a Parallel Randomized Clinical Trial

2021 ◽  
Author(s):  
Mehri Delvarianzadeh ◽  
Abdorreza Mohammadi Nafchi ◽  
Leila Nouri ◽  
Ahmad Khosravi ◽  
Aisa Bahar ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Metabolic Control ◽  
Blood Sugar ◽  
Density Lipoprotein ◽  
Portulaca Oleracea ◽  
Significant Difference ◽  
Before And After ◽  
The Difference

Abstract Background: Diabetes is the most common chronic disease worldwide. Some herbs are used to control diabetes. Portulaca Oleracea is a type of plant that has essential fatty acid-rich leaves. Objectives: This study aimed to evaluate the effect of bread enriched with Portulaca Oleracea on metabolic control indices in patients with type 2.Methods: This parallel randomized controlled clinical trial was conducted on 104 patients with type 2 diabetes. Participants received bulk bread containing 10% Portulaca powder for 4 weeks (intervention group), the control group used their normal daily bread. At baseline and end of the study a 12 hours fasting and 2 hours later blood sample were collected to quantify plasma glucose levels and lipid profiles. The effectiveness of the intervention method was compared with the difference between the mean before and after the intervention (change score) in the two groups using t-test.Results: The results showed that after the intervention, a significant difference was found between Fasting blood sugar, cholesterol and high-density lipoprotein variables in intervention groups, but could not affect serum low-density lipoprotein, triglyceride levels, blood sugar and Glycated hemoglobin(HbA1C) It should be noted that the difference between the means of the two groups before and after the intervention indicates that there is a significant difference between the other groups except HbA1C. Conclusions: consumption of bread enriched with portulaca oleracea did have a significant impact on metabolic indices of diabetes and improvement lipid profile. It is recommended to use bread enriched with portulaca oleracea powder, areas where the staple food is bread.Trial registration in the Iranian clinical trial system with the code IRCT2011030309006010N1.

scholarly journals The effect of vitamin D therapy on glycemic control and biochemical indices in type 2 diabetic patients: a randomized, clinical trial study

2021 ◽  
Vol 25 (2) ◽  
pp. 125-133
Author(s):  
Majid Mozaffari ◽  
◽  
Hamed Hajmoradi ◽  
Alireza Moravveji ◽  
Fatemeh Sadat Asgarian ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Vitamin D ◽  
Glycemic Control ◽  
Control Groups ◽  
Significant Difference ◽  
The Mean ◽  
Biochemical Indices ◽  
And Control

Introduction: The aim of the present study was to evaluate the effect of vitamin D on glycemic control and biochemical indices in type 2 diabetes. Methods: This randomized double blind placebo-controlled clinical trial was conducted on 80 patients with type 2 diabetes mellitus (T2DM) referred to Shahid Beheshti hospital. These patients were randomly classified into case and control groups. Case group consumed 50,000 IU of vitamin D once a week for 12 weeks and control group placebo. Biochemical and lipid parameters and vitamin D3 were measured in two groups. Glycosylated hemoglobin (HbA1c) was assessed by latex enhance immunoturbidimetric assay. Results: There was no significant difference between case and control groups in terms of age, sex, body mass index and used medications. The mean vitamin D level in case and control groups before intervention was 15.06 ±3.307 and 15.83± 2.509 ng/ml and after intervention was 49.77 ±15.73 and 14.91±3.13 ng/ml respectively. The mean fast blood sugar in case and control groups after intervention was 156.565±32.23 and 147.75±35.06 mg/dl, respectively. The mean HbA1c in case and control groups before intervention was 7.59± 0.39 % and 7.66± 0.38 % and after intervention was 7.26 ± 0.60 and 7.60 ± 0.38, respectively. Moreover, significant difference was seen between case (20.2± 5.74 IU/L) and control groups (23.35± 7.80 IU/L) in terms of alanine aminotransferase, after intervention. Conclusion: According to these findings, vitamin D supplementation possibly through decreasing HbA1C and hepatic alanine aminotransferase could improve diabetes complications.

scholarly journals Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial

PeerJ ◽  
2017 ◽  
Vol 5 ◽  
pp. e3187 ◽  
Author(s):  
Skylar W. Marvel ◽  
Daniel M. Rotroff ◽  
Michael J. Wagner ◽  
John B. Buse ◽  
Tammy M. Havener ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Clinical Trial ◽  
Density Lipoprotein ◽  
Genotype Imputation ◽  
Lipid Levels ◽  
Common Genetic Variants ◽  
A Genome ◽  
Meta Analyses

Background Individuals with type 2 diabetes are at an increased risk of cardiovascular disease. Alterations in circulating lipid levels, total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides (TG) are heritable risk factors for cardiovascular disease. Here we conduct a genome-wide association study (GWAS) of common and rare variants to investigate associations with baseline lipid levels in 7,844 individuals with type 2 diabetes from the ACCORD clinical trial. Methods DNA extracted from stored blood samples from ACCORD participants were genotyped using the Affymetrix Axiom Biobank 1 Genotyping Array. After quality control and genotype imputation, association of common genetic variants (CV), defined as minor allele frequency (MAF) ≥ 3%, with baseline levels of TC, LDL, HDL, and TG was tested using a linear model. Rare variant (RV) associations (MAF < 3%) were conducted using a suite of methods that collapse multiple RV within individual genes. Results Many statistically significant CV (p < 1 × 10−8) replicate findings in large meta-analyses in non-diabetic subjects. RV analyses also confirmed findings in other studies, whereas significant RV associations with CNOT2, HPN-AS1, and SIRPD appear to be novel (q < 0.1). Discussion Here we present findings for the largest GWAS of lipid levels in people with type 2 diabetes to date. We identified 17 statistically significant (p < 1 × 10−8) associations of CV with lipid levels in 11 genes or chromosomal regions, all of which were previously identified in meta-analyses of mostly non-diabetic cohorts. We also identified 13 associations in 11 genes based on RV, several of which represent novel findings.

scholarly journals Serum Selenium Status in Patients with Type 2 Diabetes and Control Group

2016 ◽  
Vol 9 (5) ◽  
pp. 234
Author(s):  
Zahra Heidari ◽  
Zahra Sepehri ◽  
Aleme Doostdar
Keyword(s):  
Type 2 Diabetes ◽  
Serum Level ◽  
Control Group ◽  
Diabetic Patients ◽  
Diabetes Incidence ◽  
Serum Selenium ◽  
Type 2 Diabetic Patients ◽  
Significant Difference ◽  
The Mean

<p>In addition to known risk factors, the role of different micronutrients such as selenium in diabetes incidence has been proposed. Some previous studies have shown an association of selenium deficiency and type 2 diabetes mellitus, while other studies have not confirmed such a relationship. The aim of this study was to evaluate serum level of selenium in patients with Type 2 diabetes compared with the control group. This cross-sectional study was carried out on patients with type 2 diabetes in Zahedan, southeastern Iran. One hundred newly diagnosed type 2 diabetic patients were evaluated for serum selenium level. One hundred subjects from the general population who had normal fasting blood sugar levels were selected as the control group. The control group subjects were matched in pairs with each of patients on the basis of sex, age (± one year), and body mass index (±1). Serum level of selenium was determined by spectrometry method. Results were compared using t-test. The mean serum level of selenium in patients was 94.47±18.07 µg/L whereas in control group was 142.79±23.67 µg/L. The mean serum level of selenium was significantly different between the two groups (P&lt;0.001). Serum levels of selenium in diabetic patients with significant difference statistically were lower than the control group. In order to evaluate serum level of selenium in patients with diabetes, studies with larger sample size are required. Likewise, prospective studies along with selenium supplementation and investigating its effect on incidence of diabetes are accordingly needed.</p>

scholarly journals Correlation between glycated hemoglobin HbA1c and serum lipid profile in patients with type 2 diabetes

2021 ◽  
pp. 14-18
Author(s):  
Asmaa Alboueishi
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Blood Glucose ◽  
Serum Lipid ◽  
Clinical Laboratory ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Diabetic Patients

Background: Hyperlipidemia is a common risk factor for diabetes that leads to cardiovascular disease, one of the causes of death of diabetic patients. Theaimof this study was to investigate the association between HbA1c levels and serum lipids in Libyan patients withtype 2 diabetes. Material and methods: The study was conducted in 2019 on 325 patients (174 males, 151 females) with type 2 diabetes referred to a private clinical laboratory in Tripoli, Libya. Blood samples were collected for measurement of HbA1c, fasting blood glucose and serum lipid concentrations. Diabetes was defined according to the American Diabetes Association criteria.The data were analyzed using an independent t-test and Pearson’scorrelation test.Results: The ages of the patients ranged from 40 to 83 years, with a mean of 51.52 ± 14.32 years SD. No significant correlation between HbA1c and age was noted (r=0.011, p=0.063). There was a significant positive correlation betweenHbA1c level and fasting blood glucose (r =0.641, p=0.000), low-density lipoprotein (r = 0.240, p = 0.000), total cholesterol (r = 0.223, p = 0.000) and triglycerides(r=0.140,p 0.067). The correlation between HbA1c and high-density lipoprotein-C was negative but not significant (r= -0.088, p = 0.123). Conclusion: HbA1c could be used as a predictor of dyslipidemia and thus it may serve as anindicator of the development of cardiovascular disease in patients with type-2 diabetes mellitus.

scholarly journals Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

2019 ◽  
Vol 18 (1) ◽  
Author(s):  
Kausik K. Ray ◽  
Stefano Del Prato ◽  
Dirk Müller-Wieland ◽  
Bertrand Cariou ◽  
Helen M. Colhoun ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Atherosclerotic Cardiovascular Disease ◽  
Open Label ◽  
Double Blind ◽  
Mixed Dyslipidemia

Abstract Background Individuals with diabetes often have high levels of atherogenic lipoproteins and cholesterol reflected by elevated low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), and LDL particle number (LDL-PN). The presence of atherosclerotic cardiovascular disease (ASCVD) increases the risk of future cardiovascular events. We evaluated the efficacy and safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, alirocumab, among individuals with type 2 diabetes (T2DM), high LDL-C or non-HDL-C, and established ASCVD receiving maximally tolerated statin in ODYSSEY DM-DYSLIPIDEMIA (NCT02642159) and DM-INSULIN (NCT02585778). Methods In DM-DYSLIPIDEMIA, individuals with T2DM and mixed dyslipidemia (non-HDL-C ≥ 100 mg/dL; n = 413) were randomized to open-label alirocumab 75 mg every 2 weeks (Q2W) or usual care (UC) for 24 weeks, with UC options selected before stratified randomization. In DM-INSULIN, insulin-treated individuals with T2DM (LDL-C ≥ 70 mg/dL; n = 441) were randomized in a double-blind fashion to alirocumab 75 mg Q2W or placebo for 24 weeks. Study participants also had a glycated hemoglobin < 9% (DM-DYSLIPIDEMIA) or < 10% (DM-INSULIN). Alirocumab dose was increased to 150 mg Q2W at week 12 if week 8 LDL-C was ≥ 70 mg/dL (DM-INSULIN) or non-HDL-C was ≥ 100 mg/dL (DM-DYSLIPIDEMIA). Lipid reductions and safety were assessed in patients with ASCVD from these studies. Results This analysis included 142 DM-DYSLIPIDEMIA and 177 DM-INSULIN participants with ASCVD, including 95.1% and 86.4% with coronary heart disease, and 32.4% and 49.7% with microvascular diabetes complications, respectively. At week 24, alirocumab significantly reduced LDL-C, non-HDL-C, ApoB, and LDL-PN from baseline versus control. This translated into a greater proportion of individuals achieving non-HDL-C < 100 mg/dL (64.6% alirocumab/23.8% UC [DM-DYSLIPIDEMIA]; 65.4% alirocumab/14.9% placebo [DM-INSULIN]) and ApoB < 80 mg/dL (75.1% alirocumab/35.4% UC and 76.8% alirocumab/24.8% placebo, respectively) versus control at week 24 (all P < 0.0001). In pooling these studies, 66.4% (alirocumab) and 67.0% (control) of individuals reported treatment-emergent adverse events. The adverse event pattern was similar with alirocumab versus controls. Conclusions Among individuals with T2DM and ASCVD who had high non-HDL-C/LDL-C levels despite maximally tolerated statin, alirocumab significantly reduced atherogenic cholesterol and LDL-PN versus control. Alirocumab was generally well tolerated. Trial registration Clinicaltrials.gov. NCT02642159. Registered 30 December 2015 and Clinicaltrials.gov. NCT02585778. Registered 23 October 2015

scholarly journals Cardiovascular Risk Distribution in a Contemporary Polish Collective

2020 ◽  
Vol 17 (9) ◽  
pp. 3306
Author(s):  
Anita Liput-Sikora ◽  
Anna Cybulska ◽  
Wiesława Fabian ◽  
Anna Fabian-Danielewska ◽  
Marzanna Stanisławska ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Primary Care ◽  
Family History ◽  
Total Cholesterol ◽  
Positive Family History ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Medical Documentation ◽  
Significant Difference

The aim of this study was to assess the prevalence of selected risk factors for cardiovascular disease (hypertension, overweight, obesity, carbohydrate metabolism disorders, a positive family history, a lack of physical activity), and to estimate the risk of a cardiovascular incident according to the Systematic Coronary Risk Evaluation (SCORE) algorithm for patients aged 35, 40, 45, 50, and 55 years, included in a primary-care prevention program, with regard to selected variables (sex and age brackets). The study sample consisted of 2009 subjects, 63% of whom were women. The largest group was the group of 35-year-olds (27%). The research method was the analysis of medical documentation of primary-care patients living in West Pomerania included in the Program of Prevention and Early Detection of Cardiovascular Disease of the National Health Fund. We collected data concerning risk factors for cardiovascular disease, blood pressure, anthropometric measurements (arm circumference, waist circumference, height, weight), body mass index (BMI), and the levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), and fasting glucose, as well as the SCORE results. Men more often than women were overweight and obese, had hyperglycemia, and had elevated levels of total cholesterol, LDL cholesterol, and triglycerides (p < 0.001). There was also a statistically significant difference in the odds of a cardiovascular incident (p < 0.001)—the SCORE results obtained by men were higher. Men require special preventive measures in order to reduce their risk factors for cardiovascular disease, especially hypertension, dyslipidemia, diabetes, overweight, obesity, smoking, and a positive family history.

Sign in / Sign up

Export Citation Format

Share Document